ARG63903

anti-CDKN2A / p16INK4a antibody

Ordering Information

Package

Price (USD)

100 μg

429.00

50 μg

299.00

Add to cart

Datasheet
Review (1)

Overview

Product Description	Goat Polyclonal antibody recognizes CDKN2A / p16INK4a
Tested Reactivity	Hu
Tested Application	IHC-P, WB
Specificity	This antibody is expected to recognise isoform p16INK4a (NP_000068.1) and isoform p16gamma (NP_001182061.1).
Host	Goat
Clonality	Polyclonal
Isotype	IgG
Target Name	CDKN2A / p16INK4a
Antigen Species	Human
Immunogen	C-HARIDAAEGPSDIPD
Conjugation	Un-conjugated
Alternate Names	Alternative reading frame; CDK4I; P19ARF; P16INK4A; CDKN2; Tumor suppressor ARF; MTS-1; P14; P16; P19; Cyclin-dependent kinase inhibitor 2A; P16INK4; MLM; p14ARF; MTS1; INK4; TP16; P16-INK4A; CMM2; ARF; P14ARF; INK4A

Application Instructions

Application Suggestion

Tested Application	Dilution
IHC-P	5 µg/ml
WB	0.1 - 1 µg/ml

Application Note

WB: Recommend incubate at RT for 1h.
IHC-P: Antigen Retrieval: Steam tissue section in Citrate buffer (pH 6.0).
* The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist.

Properties

Form	Liquid
Purification	Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Buffer	Tris saline (pH 7.3), 0.02% Sodium azide and 0.5% BSA
Preservative	0.02% Sodium azide
Stabilizer	0.5% BSA
Concentration	0.5 mg/ml
Storage Instruction	For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use.
Note	For laboratory research only, not for drug, diagnostic or other use.

Bioinformation

Database Links	GeneID: 1029 Human CDKN2A Swiss-port # P42771 Human Cyclin-dependent kinase inhibitor 2A
Gene Symbol	CDKN2A
Background	This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, MDM1, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Jul 2008]
Highlight	Related products: CDKN2A antibodies; CDKN2A Duos / Panels; Anti-Goat IgG secondary antibodies; Related news: Senescence Marker Antibody Panel is launched
Research Area	Chondrogenesis Study antibody
Calculated MW	14 kDa
PTM	Ubiquitinated in normal cells by TRIP12 via the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination at the N-terminus, regardeless of the absence of lysine residues. Ubiquitination leads to its proteasomal degradation. In cancer cells, however, TRIP12 is located in a different cell compartment, preventing ubiquitination and degradation.